PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes, metabolic and cardiovascular disease. The company's proprietary platform technology uses elastin-like biopolymers (ELPs) to increase the half-life, bioavailability, efficacy and ease of administration of therapeutic drugs and to reduce their side effects. ELPs have been engineered to control the rate of absorption into the circulation which results in a steady state pharmacokinetic profile exhibiting a unique combination of slow absorption and prolonged half-life providing an optimal drug exposure. The company's lead development candidates are Glymera, a GLP-1 analogue for type 2 diabetes, Vasomera, a vasoactive intestinal peptide (VIP) agonist for uncontrolled hypertension, acute and chronic heart failure and pulmonary arterial hypertension, and Insumera, a novel mature insulin ELP-fusion. PhaseBio is a privately owned company with headquarters and research laboratories in Malvern, Pennsylvania.